Interviews

Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center, discusses adding rituximab to venetoclax to allow for a 2-year fixed-duration treatment schedule for patients with chronic lymphocytic leukemia (CLL).

Brian Lehman, MBA, MHA, RPh, director, Medical Account Management and Strategic Alliances, Sandoz, discusses the March 2020 transition of insulin to the biologics pathway.

Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, discusses how “confirmation of sufficient likeness" should replace “totality of evidence” in biosimilar development.

Cate Lockhart, PharmD, PhD, discusses the research reports the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) plans on releasing in 2020.

Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses the impact biosimilars could make in community oncology.

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses what she will be watching closely in the biosimilars space in early 2020.

Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses challenges with reimbursement for biosimilars in community oncology practices.

Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic, discusses whether biosimilars are generating cost savings for patients with inflammatory diseases.

Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses how utilization management strategies impact patient access to biologics.

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses how patients are responding to using biosimilars.

Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses biosimilar education for patients and providers.

Tracy L. Bahl, president and chief executive officer of OneOncology, discusses the education his organization has provided to physicians on biosimilars.

Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses the role of body weight in treatment outcomes for inflammatory bowel disease (IBD).

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses how anticancer biosimilars have played a role in oncology in 2019.

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses what oncologists have learned from experience with supportive care that can be applied to adopting anticancer biosimilars.

Erich Mounce, chief operating officer, OneOncology, discusses the role that biosimilars will have in practices meeting Oncology Care Model (OCM) goals.

Brian Lehman, MBA, MHA, RPh, director, Medical Account Management and Strategic Alliances, Sandoz, discusses positive developments for biosimilars over the past year.

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses how biosimilars have impacted innovation in oncology.

Jeffrey Patton, MD, chief executive officer of Tennessee Oncology and president of physician services for OneOncology, discusses adoption of biosimilar trastuzumab, bevacizumab, and rituximab.

Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), discusses the challenges inherent in conducting large-scale comparative effectiveness research on biologics and biosimilars.

Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses the process to select the right biologic for a patient with inflammatory bowel disease (IBD).

Robin Shah, chief commercial officer of OneOncology, addresses the role that biosimilars have in community oncology.

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses the launch of the first rituximab biosimilar in the United States.

Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic, discusses how comfortable rheumatologists are with using biosimilars.

Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses financial toxicity in cancer care.

Robin Shah, chief commercial officer of OneOncology, addresses how practices can communicate the value of biosimilars to patients.

Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses how route of administration impacts patient adherence to inflammatory bowel disease (IBD) therapy.

Tracy L. Bahl, president and chief executive officer of OneOncology, discusses why his organization felt it was key to adopt biosimilars.

Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd, discusses the role that biosimilars have to play in reducing patients’ out-of-pocket costs in cancer care.

Terrill Jordan, chief executive officer of Regional Cancer Care Associates (RCCA), discusses how RCCA is handling biosimilar availability.